Passage Bio (PASG) Stock Analysis & Winston Score

Passage Bio is a clinical-stage biotechnology company working on gene therapies for rare brain diseases. Its treatments aim to deliver a working copy of a faulty gene directly into a patient's nervous system using a single infusion. The company focuses on conditions like GM1 gangliosidosis and frontotemporal dementia, which currently have few or no approved treatments. Because Passage Bio has no approved products yet, it generates no meaningful revenue. It funds its research through cash raised from investors. The company is based in Philadelphia and partners with the University of Pennsylvania's gene therapy program, which gives it access to specialized technology for delivering genes to the brain. Its main growth driver is advancing its pipeline through clinical trials toward potential regulatory approval, but the key risk is significant — most experimental gene therapies never reach the market, and the company will need additional funding to continue operations.